丙戊酸钠同时给药对扑米酮及其代谢产物苯巴比妥血清水平的影响。

The effect of concurrent administration of sodium valproate on serum levels of primidone and its metabolite phenobarbital.

作者信息

Yukawa E, Higuchi S, Aoyama T

机构信息

Department of Hospital Pharmacy, Kyushu University Hospital, Faculty of Medicine, Fukuoka, Japan.

出版信息

J Clin Pharm Ther. 1989 Oct;14(5):387-92. doi: 10.1111/j.1365-2710.1989.tb00261.x.

DOI:10.1111/j.1365-2710.1989.tb00261.x

PMID:2511216

Abstract

The effect of associated therapy on serum primidone (PRM) and derived phenobarbital (PB) concentrations, and on serum concentrations to PRM dose ratios (L/D ratio) were evaluated retrospectively from 100 consecutive PRM and derived PB determinations in 100 chronically treated epileptic patients. PRM administered was significantly (P less than 0.01) correlated with both serum PRM (r = 0.799 approximately 0.933) and derived PB levels (r = 0.545 approximately 0.870) in patients taking PRM. Derived PB L/D ratios and PB/PRM concentration ratios were higher in patients taking PRM in combination with phenytoin (PHT) and/or sodium valproate (VPA). Therefore, serum levels of PRM and derived PB should be monitored closely in patients taking PRM with PHT and/or VPA.

摘要

从100例长期接受治疗的癫痫患者连续100次的扑米酮（PRM）及代谢产物苯巴比妥（PB）测定结果中，回顾性评估联合治疗对血清PRM及PB浓度，以及血清浓度与PRM剂量比值（L/D比值）的影响。接受PRM治疗的患者中，所服用的PRM剂量与血清PRM（r = 0.799至0.933）及代谢产物PB水平（r = 0.545至0.870）均显著相关（P < 0.01）。联合服用苯妥英（PHT）和/或丙戊酸钠（VPA）的PRM治疗患者，其PB L/D比值及PB/PRM浓度比值更高。因此，对于同时服用PRM与PHT和/或VPA的患者，应密切监测血清PRM及代谢产物PB水平。